Advertisement

THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS

      Three fluorine-18-labelled tracers are currently commercially available to measure cerebral amyloid pathology and assist in the diagnosis of Alzheimer’s Disease (AD); Florbetapir, Flutemetamol and Florbetaben. FDA/EMA approved visual rating guidelines to determine if a scan is positive or negative differ considerably in regards to suggested color scale, intensity scaling, definitions of a region and signal thresholds to determine positivity. Standardization of visual reading would be highly desirable to ensure that diagnostic classification, patient selection and therapeutic decisions are comparable, independently of the tracer and reader.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'